Zymeworks rejects All Blue’s $773M offer as an ‘opportunistic’ public attack
Zymeworks rejects All Blue’s $773M offer as an ‘opportunistic’ public [...]
Not an ‘excellent outcome’ for Athersys stock as stem cell therapy misses endpoint in Japanese trial
Not an ‘excellent outcome’ for Athersys stock as stem cell [...]
100% overall survival data for gene therapy fuel Rocket for flight to regulators
100% overall survival data for gene therapy fuel Rocket for [...]
Death triggers FDA hold on Foghorn blood cancer clinical trial, shrouding timing of data drop
Death triggers FDA hold on Foghorn blood cancer clinical trial, [...]
Bayer pulls plug on $670M CAR-T cell therapy pact with Atara in wake of patient death
Bayer pulls plug on $670M CAR-T cell therapy pact with [...]
Chutes & Ladders—Aquestive CEO heads for the exits while seizure med remains in regulatory limbo
Chutes & Ladders—Aquestive CEO heads for the exits while seizure [...]
Inceptor Bio to use $37M series A to nudge CAR-T toward clinic, establish manufacturing base
Inceptor Bio to use $37M series A to nudge CAR-T [...]
Amgen celebrates 25 years of deCODE Genetics as partnership evolves from discovery to development
Amgen celebrates 25 years of deCODE Genetics as partnership evolves [...]
Enanta sinks to multiyear low as phase 2b RSV trial flames out
Enanta sinks to multiyear low as phase 2b RSV trial [...]
Nanobiotix scales down R&D plan, freezes hiring to close gap between cash runway and phase 3 data
Nanobiotix scales down R&D plan, freezes hiring to close gap [...]